Chimeric lyssavirus nucleic acids and polypeptides

Details Chimeric lyssavirus nucleic acids and polypeptides Chimeric lyssavirus nucleic acids and polypeptides

2007-07-03

2007-07-03

Campell, Bruce R. (Department: 1648)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C424S224100, C424S202100, C435S091100, C435S091330, C435S236000, C435S320100

Reexamination Certificate

active

09958672

ABSTRACT:
The present invention provides chimeric nucleic acids, preferably contained on an expression vector, that encode chimeric immunogenic polypeptides. The nucleic acids encode at least site III of alyssavirusglycoprotein, which has been found to improve the immunogenicity oflyssavirusepitopes for protection from rabies. The chimeric nucleic acids and proteins can also contain antigenic determinants for epitopes other than those oflyssavirus. Thus, the invention provides chimeric nucleic acids and polypeptides that elicit a strong immune response to multiple antigens. Use of the methods of the present invention permits DNA vaccination without the need to supply multiple antigens on separate DNA molecules.

REFERENCES:
patent: 4393201 (1983-07-01), Curtis et al.
patent: 6673601 (2004-01-01), Jacob et al.
patent: 696 191 (1994-10-01), None
patent: WO 90 11092 (1990-10-01), None
patent: WO 93 06223 (1993-04-01), None
patent: WO 95/09249 (1995-04-01), None
Fields et al. Virology 3rd edition. p. 1142-1143.
BioDirectoryä' 98 by Amershanpharmaciabiotech pp. 126-127 published 1998.
Bahloul et al. Vaccine 1998, vol. 15, No. 4, pp. 417-425.
Xiang et al. Virology. 1995, vol. 209, pp. 569-579.
Yarosh et al. Vaccine. 1996, vol. 14, No. 13, pp. 1257-1264.
Taylor et al. Vaccine. 1995, vol. 13, No. 6, pp. 539-549.
Mebatsion et al. J. Virol. 1995, vol. 69, No. 3, pp. 1444-1451.
Prehaud et al. Virology. 1989, vol. 173, No. 2, pp. 390-399.
Xuan et al. Vaccine. May-Jun. 1998, vol. 16, No. 9/10, pp. 969-976.
Macfarlan, R., I., et al. T Cell resposes to cleaved rabies virus glycoprotein and to synthetic peptides, J. Immunology, vol. 133., pp. 2748-2752 (1984).
Lafon, M., et al., Use of a monoclonal antibody for quantitation of rabies vaccine glycoprotein by enzyme immunoassay, J. Biological Standardization, vol. 13, pp. 295-301 (1985).
Wunner, W.H., et al., Localization of imunogenic domains on the rabies virus glycoprotein, Ann. Inst. Pateur/Virol., vol. 136E, pp. 353-362 (1985).
Perrin, P., et al., Rabies immunosome (subunit vaccine) structure and immunogenicity. Pre- and post-exposure protection studies, Vaccine, vol. 3, pp. 325-332 (1985).
Perrin, P., et al., The influence of the type of immunosorbent on rabies antibody EIA; advantages of purified glycoprotein over whole virus, J. Biological Standardization, vol. 14, pp. 95-102 (1986).
Rogers, S., et al., Amino acid sequences common to rapidly degraded proteins: The PEST hypothesis, Science, vol. 234, pp. 364-369 (1986).
Perrin, P. et al. Interleukin increases protection against experimental rabies, Immunobiology, vol. 177, pp. 199-209 (1988).
Glaudin, Y., et al., Reversible conformational changes and fusion activity of rabies virus glycoprotein, J. Virology, vol. 65, pp. 4853-4859 (1991).
Xiang, Z. Q., et al., Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus, Virology, vol. 199, pp. 132-140 (1994).
Gaudin, Y. et al., Biological function of the low-pH, fusion-inactive conformation of rabies virus glycoprotein (G):G is transported in a fusion inactive state-like conformation, J. Virology, vol. 69: 5528-5534 (1995).
Editorial, Vaccine, vol. 14, (1996), pp. 579, 691-700.
Perrin, P., et al., The antigen-specific cell-mediated immune response in mice is suppressed by infection with pathogenic lyssaviruses, Research Virology, vol. 147, pp. 289-299 (1996).
Perrin, P., Techniques for the preparation of rabies conjugates,in Laboratory Techniques in Rabies, Meslin, F-X, Kaplan, M., and Koprowski, H., eds. pp. 433-445 (1996).
Smith, J.S., et al., A rapid fluorescent focus inhibition test (RFFIT) for determining rabies virus-neutralizing antibody,in Laboratory Techniques in Rabies, Meslin, F-X, Kaplan, M., and Koprowski, H., eds. pp. 181-189 (1996).
Amengual, B., et al., Evolution of European bat lyssaviruses, J. General Virology, vol. 78, pp. 2319-2328 (1997).
Donnelly, J.J., et al., DNA Vaccines, Ann. Rev. Immunology, vol. 15, pp. 617-648 (1997).
Gaudin, Y., Folding of rabies virus glycoprotein: epitope acquisition and interaction with endoplasmic reticulum chaperones, J. Virology, vol. 71, pp. 3742-3750 (1997).
Lang, J., et al., Radomised feasibility trial of pre-exposure rabies vaccination with DTP-IPV in infants, Lancet, vol. 349, pp. 1663-1665 (1997).
Pastoret, P.P., et al., Part 2: Vaccination Against Rabies,in Veterinary Vaccinology, Pastoret, P-P. et al. eds., pp. 616-628 (1997).
Coulon, P., et al., An avirulent mutant of rabies virus is unable to infect motoneurons in vivo and in vitro, J. Virology, vol. 72, pp. 273-278 (1998).
Tuffereau, C., et al., Neuronal cell surface molecules mediate specific binding to rabies virus glycoprotein expressed by a recombinant baculovirus on the surfaces of Lepidopteran cells, J. Virology, vol. 72, pp. 1085-1091 (1998).
Lodmell, D., L., et al., DNA immunization protects nonhuman primates against rabies virus, Nature Medicine, vol. 4, pp. 949-952 (1998).
Lodmell, D. L., et al., Gene gun particle-mediated vaccination with plasmid DNA confers protective immunity against rabies virus infection, Vaccine, vol. 16, pp. 115-118 (1998).
Thomson, S. A., et al., Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination, J. Immunology, pp. 1717-1723 (1998).
U.S. Appl. No. 10/608,538, filed Jun. 30, 2003, Jacob et al.
Benmansour et al., “Antigenicity of Rabies Virus Glycoprotein”,J. Virol., 65(8):4198-4203 (1991).
Buffett et al., “P. Falciparum DomainDomain Mediating Adhesion to Chondroitin Sulfate A: A Receptor for Human Placental Infection”,PNAS, 96(22):12743-48 (1999).
Dietzschold et al., “Structural and Immunological Characterization of a Linear Virus-Neutralizing Epitope of the Rabies Virus Glycoprotein and its Possible Use in a Synthetic Vaccine”,Vaccine, 64(8):3804-3809 (1990).
Ertl., et al., “Novel Vaccine Approaches”,Journal of Immunology, 156:3579-3582 (1996).
European Commission COST/STD-3, “Advantages of Combined Vaccines”,Vaccine, 14(7):693-700 (1996).
Lafay et al., “Immunodominant Epitopes Defined by a Yeast-expressed Library of Random Fragments of the Rabies Virus Glycoprotein Map Outside Major Antigenic Sites”,J.Gen. Virol., B77:339-346 (1996).
Liu et al., “Polynucleotide Vaccines:A Potential New Generation of Vaccines,”Proc. Eur. Assoc. Vet. Pharmacol. Toxicol. 6 Meet., 301, Abstract Only (1994).
Macy et al.,Vet. Clin. North Am small Anim. Pract., Abstract Only, 26(1):103-109 (1996).
Mebatsion et al., “Mokola Virus Glycoprotein and Chimeric Proteins Can Replace Rabies Virus Glycoprotein in the Rescue of Infectious Defective Rabies Virus Particles”,Journal of Virology, 69(3):1444-1451 (1995).
Paoletti et al.,PNAS, 93(21):11349-53 (1996).
Tine et al., “NYVAC-Pf7:A Poxvirus-vectored, Multiantigen, Multistage Vaccine Candidate for Plasmodium Falciparum Malaria,”Infection and Immunity., 64(9):3833-3844 (1996).
International Search Report in corresponding PCT/IB00/00564.
Jallet et al.; Chimeric lyssavirus glycoproteins with increased immunological potential; J. Virol., (1999) pp. 225-233.
Bahloul et al.; DNA-based immunization for exploring the enlargement of immunological cross-reactivity against the lyssaviruses; Vaccine; (1998) vol. 16, No. 4, pp. 417-425.
Desméziéres et al.; Lyssavirus glucoproteins expressing immunologically potent foreign B cell and cytotoxic T lymphocyte epitopes as prototypes for multivalent vaccines; J. Gen. Virol. (1999), 80:2343-2351.

Affiliated with

Also associated with

Rating

Chimeric lyssavirus nucleic acids and polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Chimeric lyssavirus nucleic acids and polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric lyssavirus nucleic acids and polypeptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3801396